Presidio Medical

Presidio Medical is a clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF) neuromodulation platform to treat diseases of undesired neural activity, with an initial focus on chronic pain management. The company's technology leverages the scientific principles discovered by Nobel Prize winners Alan Hodgkin and Andrew Huxley in 1963, concerning the ionic mechanisms involved in nerve cell excitation and inhibition.

Unlike traditional neuromodulation devices that use short pulses for neural activation, Presidio's proprietary ULF technology enables controlled and reversible inhibition of pain neurons through sodium channel inactivation. This groundbreaking approach represents a significant advancement in neuromodulation therapy, offering a potential solution for cases where neural inhibition may be more desirable than excitation.

Presidio's ULF therapy has undergone clinical trials involving over 50 patients with chronic pain, with remarkable early results. Patients reported an average of more than 90% pain relief after 15 days of treatment, highlighting the therapy's potential effectiveness.

The company's technology platform is founded on Nobel Prize-winning basic science principles and has been brought to life through advances in engineering sciences and extensive research and development efforts.

In June 2023, Presidio Medical announced the successful closure of a USD 72 million Series C funding round, led by Deerfield Management, Invus Opportunities, Action Potential Venture Capital, and ShangBay Capital. The proceeds from this funding will be utilized to expand the company's team, scale manufacturing operations, and conduct long-term, pivotal clinical studies to further demonstrate the durability and efficacy of the ULF neuromodulation platform.